Note: EPS may not be comparable

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of $, versus ($0.52) reported last year. Revenue for the quarter came in at $487 thousand versus the consensus estimate of $520 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.